Trial Profile

Phase ll Study of a BET Inhibitor, ZEN003694, Combined With a PARP Inhibitor, Talazoparib, in Patients With Recurrent Ovarian Cancer

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 27 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Talazoparib (Primary) ; ZEN 3694 (Primary)
Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
Focus Therapeutic Use

Most Recent Events

22 Jun 2025 Planned End Date changed from 1 Mar 2031 to 1 Mar 2033.
22 Jun 2025 Planned primary completion date changed from 1 Dec 2029 to 31 Dec 2031.
27 Nov 2023 Planned End Date changed from 1 Nov 2027 to 1 Mar 2031.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com